Phase 4 Multiple Sclerosis Clinical Trials
20 recruitingPhase 4
What is a Phase 4 trial?
Phase 4 trials, also called post-marketing studies, are conducted after a treatment has been approved and is available to the public. They monitor long-term effectiveness and safety in a broader population.
Showing 1–20 of 20 trials
Recruiting
Phase 4
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis
Novartis Pharmaceuticals30 enrolled6 locationsNCT04480853
Recruiting
Phase 4
Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis
Multiple SclerosisLower Urinary Track Symptoms
Atlantic Health System60 enrolled1 locationNCT07614321
Recruiting
Phase 4
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
Relapsing Multiple SclerosisPrimary Progressive Multiple Sclerosis
Hoffmann-La Roche60 enrolled17 locationsNCT07483450
Recruiting
Phase 4
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
Relapsing-remitting Multiple Sclerosis (RRMS)
Novartis Pharmaceuticals224 enrolled14 locationsNCT06733922
Recruiting
Phase 4
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Multiple Sclerosis
Johns Hopkins University50 enrolled1 locationNCT07389590
Recruiting
Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)123 enrolled12 locationsNCT05285891
Recruiting
Phase 4
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remitting
Northwestern University40 enrolled1 locationNCT07225361
Recruiting
Phase 4
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
MGH Institute of Health Professions48 enrolled1 locationNCT06136728
Recruiting
Phase 4
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Novartis Pharmaceuticals20 enrolled22 locationsNCT06444113
Recruiting
Phase 4
Glucose Consumption in MS Using [F-18]FDG-PET
Multiple Sclerosis
Brigham and Women's Hospital50 enrolled1 locationNCT07087106
Recruiting
Phase 4
Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities
Multiple SclerosisSpinal Cord InjuryCentreal Neurological Condition+1 more
Oxford University Hospitals NHS Trust50 enrolled1 locationNCT07303582
Recruiting
Phase 4
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
Relapsing Multiple Sclerosis
University of Colorado, Denver100 enrolled3 locationsNCT06529406
Recruiting
Phase 4
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
University of California, San Francisco5 enrolled1 locationNCT06495593
Recruiting
Phase 4
B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Amsterdam UMC, location VUmc296 enrolled1 locationNCT05296161
Recruiting
Phase 4
Home Based Infusions for Ocrelizumab
Multiple Sclerosis
University of Colorado, Denver110 enrolled1 locationNCT04650321
Active
Phase 3Phase 4
Long term monitoring of multiple sclerosis patients on cladribine treatment
Multiple Sclerosis
John Hunter Hospital of Hunter New England Local Health District150 enrolled9 locationsACTRN12619000257167
Not Yet Recruiting
Phase 4
A clinical and electrophysiological study of the effects of 4-aminopyridine on upper limb impairment in Multiple Sclerosis
Multiple Sclerosis
Austin Health30 enrolled1 locationACTRN12613000439741
Not Yet Recruiting
Phase 4
A placebo-controlled, randomized, double-blind trial of the effects of modified release 4-aminopyridine on upper limb impairment in Multiple Sclerosis
Multiple Sclerosis
Austin Health60 enrolled1 locationACTRN12613000331730
Not Yet Recruiting
Phase 4
Avonex dose titration study in Multiple Sclerosis
Multiple Sclerosis
Biogen Idec Australia Pty Ltd90 enrolled1 locationACTRN12607000184471
Not Yet Recruiting
Phase 3Phase 4
An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 or C-1802 and a Dosing Suspension Safety Evaluation
Multiple Sclerosis
Biogen Idec900 enrolled1 locationACTRN12605000769684